Not logged in Share Save
Share Save
Share Save
Share Save
Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01) Zhao, Chuanhua; Zhao, Jun; Chen, Yigui; Liu, Bo; Du, Yangfeng; Li, Chenglin; Zhang, Jingdong; Yang, Mudan; Liu, Ying; Bai, Yuxian; Li, Suyi; Zhang, Ruixing; Ning, Fangling; Liu, Yanping; Zou, Kai; Zhang, Qi; Xie, Yijiao; An, Yuping; Xu, Jianming Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis Wu, Xiaohua; Mao, Yimin; Xu, Nong; Bai, Yuxian; Wang, Dong; Chen, Xiaojun; Yin, Xianli; Deng, Yanhong; Yang, Jianwei; Zhang, Jieqing; Tang, Jie; Huang, Yi; Li, Jiayi; Luo, Suxia; Zheng, Hong; Zhao, Weidong; Xu, Miaomiao; Li, Nan; Mao, Yixiang; Gozman, Alexander; Xu, Jianming Share Save
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study Qin, Shukui; Bai, Yuxian; Li, Jin; Pan, Hongming; Luo, Suxia; Qu, Yanli; Ye, Feng; Yang, Lin; Liu, Tianshu; Li, Wei; Chen, Xi; Yang, Jianwei; Ying, Jieer; Lin, Xiaoyan; Zhao, Lin; Liang, Xinjun; Mao, Yixiang; Guo, Run; Zuo, Yi; Bordia, Sonal; Li, Shouguo Share Save
Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study Kato, K.; Xu, R-H.; Oh, D-Y.; Bai, Y.; Shi, J.; Lee, K-W.; Hirano, H.; Xu, H.; Sheng, T.; Barnes, G. Share Save
KEYNOTE-859 update: Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer Ryu, M. H.; Rha, S. Y.; Wyrwicz, L. S.; Weber, P. E. Yanez; Bai, Y.; Lee, J.; Herrero, F. Rivera; Alves, G. V.; Garrido, M.; Shiu, K-K.; Gonzalez Fernandez, M.; Li, J.; Lowery, M. A.; Cil, T.; Cruz, F.; Oh, D-Y.; Yin, L.; Bordia, S.; Bhagia, P.; Qin, S. Share Save
First-line tislelizumab plus chemotherapy in gastric/ gastroesophageal junction cancer: RATIONALE-305 Asian Subgroup Kato, K.; Bai, Y.; Shi, J.; Lee, K.; Wang, J.; Pan, H.; Rha, S.; Zhang, R.; Hirano, H.; Yamaguchi, K.; Guo, Z.; Ba, Y.; Yang, L.; Tsukuda, H.; Xu, Y.; Sheng, T.; Yang, S.; Li, L.; Oh, D.; Xu, R. Share Save
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial He, Mingming; Wang, Zhiqiang; Lu, Jin; Bai, Yuxian; Mao, Teng; Wang, Jun; Fan, Qingxia; Zhang, Yiping; Zhao, Kuaile; Chen, Zhendong; Gao, Shegan; Li, Jiancheng; Fu, Zhichao; Gu, Kangsheng; Liu, Zhihua; Wu, Lin; Zhang, Xiaodong; Feng, Jifeng; Niu, Zuoxing; Ba, Yi; Zhang, Helong; Liu, Ying; Zhang, Li; Min, Xuhong; Huang, Jing; Cheng, Ying; Wang, Dong; Sheng, Zhen; Zeng, Wanqin; Song, Li; Xu, Rui-Hua; Luo, Huiyan Share Save
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up Cruz-Correa, M.; Oh, D-Y.; Kato, K.; Tabernero, J.; Bai, Y.; Shi, J.; Lee, K-W.; Hirano, H.; Spigel, D. R.; Wyrwicz, L. S.; Pazo Cid, R. A.; Cubillo Gracian, A.; Li, L.; Xu, Y.; Sheng, T.; Yang, S.; Xu, R-H.; Moehler, M. Share Save
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial Wang, Feng; Shen, Lin; Guo, Weijian; Liu, Tianshu; Li, Jin; Qin, Shukui; Bai, Yuxian; Chen, Zhendong; Wang, Jufeng; Pan, Yueyin; Shu, Yongqian; Zhao, Fuyou; Cheng, Ying; Ye, Feng; Gu, Kangsheng; Zhang, Tao; Pan, Hongming; Zhong, Haijun; Zhou, Fuxiang; Qin, Yanru; Yang, Lei; Mao, Weidong; Li, Qiu; Dai, Wenxiang; Li, Wei; Wang, Shubin; Tang, Yong; Ma, Dong; Yin, Xianli; Deng, Yanhong; Yuan, Ying; Li, Man; Hu, Wenwei; Chen, Donghui; Li, Guoxin; Liu, Qiqi; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo; Xu, Rui-Hua Share Save
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial Qiu, Miao-Zhen; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Correa, Marcia Cruz; Zimina, Anastasia, V; Bai, Yuxian; Shi, Jianhua; Lee, Keun-Wook; Wang, Jufeng; Poddubskaya, Elena; Pan, Hongming; Rha, Sun Young; Zhang, Ruixing; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Chao, Yee; Wyrwicz, Lucjan; Disel, Umut; Cid, Roberto Pazo; Fornaro, Lorenzo; Evesque, Ludovic; Wang, Hongwei; Xu, Yaling; Li, Jiang; Sheng, Tao; Yang, Silu; Li, Liyun; Moehler, Markus; Xu, Rui-Hua Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
